AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Anika Therapeutics Inc
XNAS · usd
SIC 3841 · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
FIGI BBG001S609X7
21.42▲ 0.33 (1.56%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
21.09
Day's Range
20.60 – 21.45
52-Week Range
9.00 – 22.88
Volume
58.8K
Avg Volume
98.0K
Share Statistics
Shares Outstanding
Employees
235
Exchange
XNAS
Listed
1993-05-03
Share count as of July 24, 2026

Anika Therapeutics Inc (ANIK) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Anika Therapeutics Inc (ANIK)
What is Anika Therapeutics Inc's Market Cap?
Anika Therapeutics Inc's Market Cap is $286.7M, based on as-reported figures from SEC (XBRL) filings.
What is Anika Therapeutics Inc's Enterprise Value?
Anika Therapeutics Inc's Enterprise Value is $248.3M, based on as-reported figures from SEC (XBRL) filings.
What is Anika Therapeutics Inc's Price / Sales?
Anika Therapeutics Inc's Price / Sales is 2.4×, based on as-reported figures from SEC (XBRL) filings.
What is Anika Therapeutics Inc's EV / Revenue?
Anika Therapeutics Inc's EV / Revenue is 2.1×, based on as-reported figures from SEC (XBRL) filings.
What is Anika Therapeutics Inc's EV / EBITDA?
Anika Therapeutics Inc's EV / EBITDA is 487.7×, based on as-reported figures from SEC (XBRL) filings.
What is Anika Therapeutics Inc's Revenue (TTM)?
Anika Therapeutics Inc's Revenue (TTM) is $120.7M, based on as-reported figures from SEC (XBRL) filings.
What is Anika Therapeutics Inc's Net Income (TTM)?
Anika Therapeutics Inc's Net Income (TTM) is -$3.8M, based on as-reported figures from SEC (XBRL) filings.
What is Anika Therapeutics Inc's EBITDA?
Anika Therapeutics Inc's EBITDA is $500.0K, based on as-reported figures from SEC (XBRL) filings.
What is Anika Therapeutics Inc's Diluted EPS (TTM)?
Anika Therapeutics Inc's Diluted EPS (TTM) is -0.28, based on as-reported figures from SEC (XBRL) filings.
What is Anika Therapeutics Inc's EBITDA Margin?
Anika Therapeutics Inc's EBITDA Margin is 0.4%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ANIKAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
YoY growth+15.6%+13.2%+0.0%-5.9%
Cost of revenue
Gross profit
% of revenue65.1%64.2%62.6%56.0%
Operating expenses:
Research & development
Selling, general & administrative
Total operating expenses
% of revenue56.1%82.7%60.5%67.6%
Income (loss) from operations
% of revenue9.1%-18.5%2.1%-11.6%
Interest and other income, net
Income (loss) before income taxes
Provision for income taxes
Income (loss) from continuing operations
Income (loss) from discontinued operations, net of tax
Net income (loss)
% of revenue10.1%-17.1%1.0%-8.4%
Earnings Per Share, Basic
Earnings Per Share, Diluted